A Phase 2 interventional study of Nilotinib and DTIC in Melanoma, sponsored by Novartis Pharmaceuticals. Completed at 49 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Melanoma by Novartis — 1 open to participants now, 6 under way, none of them phase 3. Melanoma · Novartis.
Among the 51 studies in Melanoma by Novartis, this one is the 30th largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2010, is one of 10 in phase 2, and was the 7th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →1 of the 51 studies in Melanoma by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 12 more countries
Ages 18–100
By country, each count listing its studies:
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 17 · Phase 3 5 · Phase 4 2
First in 1998; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is above the median of 40 across 2,650 interventional studies indexed under Melanoma.
Median enrollment 134 across the 35 interventional studies, 379 across the 14 observational. Of the 43 that completed or were terminated, 18 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
4 of the studies in Melanoma by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04417621Novartis PharmaceuticalsStudy of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | 2027-02-02 |
| NCT03891953Novartis PharmaceuticalsStudy of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | 2027-06-25 |
| NCT05415072Novartis PharmaceuticalsA Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | 2027-10-01 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 51 studies in Melanoma by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation.
This trial began as a multi-center, randomized, Phase III, controlled trial for nilotinib vs (DTIC) dacarbazine to assess the efficacy and safety of nilotinib (400 mg bid) in patients with c-Kit mutated metastatic and/or inoperable melanoma. The study was open to patients with mucosal or acral melanoma.
Due to substantial difficulties identifying and recruiting eligible patients, the trial design was altered from a randomized, two-arm, Phase III study to a single-arm, Simon two-stage Phase II study with protocol Amendment 2 (27-Jul-2011). While the original protocol required the recruitment of 120 patients, this amendment required the study to recruit only 41 patients (patients randomized to nilotinib prior to Amendment 2 were to be counted in this total, but those randomized to dacarbazine ( DTIC ) DTIC were not). Patients randomized to DTIC were allowed to cross-over to nilotinib, either immediately or at the time of progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may have applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
400 mg twice daily
Drug: Nilotinib
850 mg/m2 IV every 3 weeks
Drug: DTIC
Overall Response Rate (ORR)
ORR was defined as the proportion of participants with a best overall response (BOR) of a confirmed complete response or partial response (CR+PR) determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) based on local investigators' assessment (CT/MRI/photography). Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.
Time frame: End of study (up to 39 months)
Durable Overall Response Rate (DORR)
DORR was defined as the rate of best overall response (CR+PR) lasting at least 12 weeks determined by RECIST v1.0 based on local investigators' assessment (CT/MRI/photography). The duration of ORR responders is computed from the date of first documented response (CR/PR) to the date of first documented progression or death due to underlying disease. Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no worsening of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.
Time frame: End of study (up to 39 months)
Progression Free Survival (PFS)
PFS was defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Progression is defined using RECIST v1.0, as a \>=20% increase in the sum of longest diameter of all target lesions, from smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or unequivocal progression of non-target lesions.
Time frame: End of study (up to 39 months)
Overall Survival (OS)
OS was defined as the time from the date of the start of treatment to the date of death due to any cause.
Time frame: End of study (up to 39 months)
Time to Objective Response (TOR)
TOR was defined as the time between the start date of treatment until first documented confirmed response of CR or PR determined by RECIST v1.0 based on local investigators' assessment (CT/MRI/photography). Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.
Time frame: End of study (up to 39 months)
Disease Control Rate (DCR)
DCR was defined as the proportion of participants with an overall response of CR of any duration, PR of any duration, or stable disease (SD) for a minimum of 12 weeks from start of treatment. Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions; PD, a \>=20% increase in TLs, clearly worsening of non-TLs, or emergence of new lesions; SD: no change or small changes that do not meet previously given criteria for CR, PR or PD.
Time frame: End of study (up to 39 months)
PFS Rate
PFS was defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Progression is defined using RECIST v1.0, as a \>=20% increase in the sum of longest diameter of all target lesions, from smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or unequivocal progression of non-target lesions.
Time frame: End of study (up to 39 months)
OS Rate
OS was defined as the time from the date of the start of treatment to the date of death due to any cause.
Time frame: End of study (up to 39 months)
| Milestone | Nilotinib | DTIC |
|---|---|---|
| Started | 42 | 13 |
| Cross over from dtic to nilotinib | 0 | 10 |
| Completed | 4 | 0 |
| Not completed | 38 | 13 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Disease progression | 33 | 9 |
| Withdrew: Administrative problems | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Crossover to nilotinib w/out progression | 0 | 2 |
| Withdrew: Adverse event | 2 | 0 |
ORR was defined as the proportion of participants with a best overall response (BOR) of a confirmed complete response or partial response (CR+PR) determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) based on local investigators' assessment (CT/MRI/photography). Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.
| Participants | Nilotinib | DTIC |
|---|---|---|
| Overall Response Rate (ORR) | 11 | 3 |
DORR was defined as the rate of best overall response (CR+PR) lasting at least 12 weeks determined by RECIST v1.0 based on local investigators' assessment (CT/MRI/photography). The duration of ORR responders is computed from the date of first documented response (CR/PR) to the date of first documented progression or death due to underlying disease. Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no worsening of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.
| Participants | Nilotinib | DTIC |
|---|---|---|
| Durable Overall Response Rate (DORR) | 11 | 3 |
PFS was defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Progression is defined using RECIST v1.0, as a \>=20% increase in the sum of longest diameter of all target lesions, from smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or unequivocal progression of non-target lesions.
| Months | Nilotinib | DTIC |
|---|---|---|
| Progression Free Survival (PFS) | 4.2 (2.1 to 5.8) | 4.2 (0.8 to 8.0) |
OS was defined as the time from the date of the start of treatment to the date of death due to any cause.
| Months | Nilotinib | DTIC |
|---|---|---|
| Overall Survival (OS) | 18.0 (10.9 to 20.3) | 22.8 (4.9 to NA) |
TOR was defined as the time between the start date of treatment until first documented confirmed response of CR or PR determined by RECIST v1.0 based on local investigators' assessment (CT/MRI/photography). Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.
| months | Nilotinib | DTIC |
|---|---|---|
| Time to Objective Response (TOR) | NA (NA to NA) | NA (NA to NA) |
DCR was defined as the proportion of participants with an overall response of CR of any duration, PR of any duration, or stable disease (SD) for a minimum of 12 weeks from start of treatment. Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions; PD, a \>=20% increase in TLs, clearly worsening of non-TLs, or emergence of new lesions; SD: no change or small changes that do not meet previously given criteria for CR, PR or PD.
| Participants | Nilotinib | DTIC |
|---|---|---|
| Disease Control Rate (DCR) | 20 | 7 |
PFS was defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Progression is defined using RECIST v1.0, as a \>=20% increase in the sum of longest diameter of all target lesions, from smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or unequivocal progression of non-target lesions.
| Percentage of participants | Nilotinib | DTIC |
|---|---|---|
| PFS Rate | 34.6 | 23.1 |
OS was defined as the time from the date of the start of treatment to the date of death due to any cause.
| Percentage of participants | Nilotinib | DTIC |
|---|---|---|
| OS Rate | 63.6 | 66.7 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nilotinib | — | 12/42 (28.6%) | 40/42 (95.2%) |
| DTIC | — | 1/13 (7.7%) | 9/13 (69.2%) |
| Crossover Nilotinib Treatment | — | 4/10 (40%) | 10/10 (100%) |
| Event | Nilotinib | DTIC | Crossover Nilotinib Treatment |
|---|---|---|---|
| ArrhythmiaCardiac disorders | 0/42 | 0/13 | 1/10 |
| Myocardial infarctionCardiac disorders | 0/42 | 0/13 | 1/10 |
| Retinal detachmentEye disorders | 0/42 | 0/13 | 1/10 |
| Abdominal painGastrointestinal disorders | 2/42 | 0/13 | 1/10 |
| AscitesGastrointestinal disorders | 0/42 | 0/13 | 1/10 |
| General physical health deteriorationGeneral disorders | 0/42 | 0/13 | 1/10 |
| Oedema peripheralGeneral disorders | 0/42 | 0/13 | 1/10 |
| Herpes zoster cutaneous disseminatedInfections and infestations | 0/42 | 0/13 | 1/10 |
| InfectionInfections and infestations | 0/42 | 0/13 | 1/10 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/42 | 0/13 | 1/10 |
| Event | Nilotinib | DTIC | Crossover Nilotinib Treatment |
|---|---|---|---|
| RashSkin and subcutaneous tissue disorders | 20/42 | 2/13 | 3/10 |
| Blood bilirubin increasedInvestigations | 19/42 | 1/13 | 3/10 |
| NauseaGastrointestinal disorders | 18/42 | 5/13 | 2/10 |
| FatigueGeneral disorders | 13/42 | 5/13 | 4/10 |
| HeadacheNervous system disorders | 6/42 | 5/13 | 3/10 |
| Decreased appetiteMetabolism and nutrition disorders | 13/42 | 2/13 | 3/10 |
| DiarrhoeaGastrointestinal disorders | 7/42 | 1/13 | 3/10 |
| AstheniaGeneral disorders | 2/42 | 1/13 | 3/10 |
| HyperglycaemiaMetabolism and nutrition disorders | 9/42 | 1/13 | 3/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/42 | 2/13 | 3/10 |
| Age, Continuous(Years) | Nilotinib | DTIC | Total |
|---|---|---|---|
| Mean | 64.7 ± 12.39 | 68.8 ± 12.99 | 66.8 ± 12.69 |
| Sex: Female, Male(Participants) | Nilotinib | DTIC | Total |
|---|---|---|---|
| Female | 23 | 8 | 31 |
| Male | 19 | 5 | 24 |
The record gives a start of Jun 2010, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib